Richard N. Kender
Executive Chair and Interim Chief Executive Officer
CEO
Board Member
Executive changes
-
Appointed Class II director to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors have been duly e at Seres Therapeutics, Inc. (MCRB)2026-07-08
- 2026-03-02
Earnings-call appearances
No earnings-call appearances recorded yet.